Immunology proves a great success for treating systemic autoimmune diseases – a perspective on immunopharmacology: IUPHAR Review 23

British Journal of Pharmacology

Volumn 174, Issue 13, 2017, Pages 1875-1880

  Ishii, Masaru ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BARICITINIB; BELIMUMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENOSUMAB; ETANERCEPT; FINGOLIMOD; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IXEKIZUMAB; JANUS KINASE INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NATALIZUMAB; OMALIZUMAB; SARILUMAB; SECUKINUMAB; SIRUKUMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CHRONIC URTICARIA; CROHN DISEASE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOPHARMACOLOGY; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS;

EID: 85018778590     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13784     Document Type: Review

References (41)

1. Ahmadzadeh V, Farajnia S, Feizi MA, Nejad RA (2014). Antibody humanization methods for development of therapeutic applications. Monoclon Antib Immunodiagn Immunother 33: 67–73.
2. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5743.
3. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The concise guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
5. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015d). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
6. Ash Z, Emery P (2012). The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 12: 1277–1289.
7. Bandzar S, Gupta S, Platt MO (2013). Crohn's disease: a review of treatment options and current research. Cell Immunol 286: 45–52.
8. Baraliakos X, Coates LC, Braun J (2015). The involvement of the spine in psoriatic arthritis. Clin Exp Rheumatol 33: S31–S35.
9. Baron R, Ferrari S, Russell RG (2011). Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48: 677–692.
10. Beare A, Stockinger H, Zola H, Nicholson I (2008). Monoclonal antibodies to human cell surface antigens. Curr Protoc Immunol Appendix 4: 4A.
11. Braun J, Kiltz U, Heldmann F, Baraliakos X (2015). Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs 20: 1–14.
12. Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A et al. (2016). Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs 21: 69–79.
13. Feldmann M, Maini SR (2008). Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223: 7–19.
14. Gomollón F (2014). Biosimilars: are they bioequivalent? Dig Dis 32 (Suppl 1): 82–87.
15. Gossec L, Smolen JS (2015). Treatment of psoriatic arthritis: management recommendations. Clin Exp Rheumatol 33: S73–S77.
16. Igawa T, Haraya K, Hattori K (2016). Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol Rev 270: 132–151.
17. Jacobs A, Rosumeck S (2015). Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis: comment. Clin Exp Dermatol 40: 810–811.
18. Jordan N, D'Cruz DP (2015). Belimumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol 11: 195–204.
19. Kaplan AP (2012). Treatment of chronic spontaneous urticarial. Allergy Asthma Immunol Res 4: 326–331.
20. Kaplan AP, Greaves M (2009). Pathogenesis of chronic urticaria. Clin Exp Allergy 39: 777–787.
21. Keating GM (2013). Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs 73: 1095–1119.
22. Köhler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497.
23. Liu L (2015). Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104: 1866–1884.
24. Loleit V, Biberacher V, Hemmer B (2014). Current and future therapies targeting the immune system in multiple sclerosis. Curr Pharm Biotechnol 15: 276–296.
25. Lubrano E, Perrotta FM (2016). Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs 76: 663–673.
26. Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA (2014). Certolizumab for rheumatoid arthritis. Clin Exp Rheumatol 32: 415–423.
27. Mascelli MA, Zhou H, Sweet R, Getsy J, Davis HM, Graham M et al. (2007). Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 47: 553–565.
28. Pelletier D, Hafler DA (2012). Fingolimod for multiple sclerosis. N Engl J Med 366: 339–347.
29. Presta LG (2006). Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58: 640–656.
30. Rothstein B, Gottlieb A (2016). Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther 16: 119–128.
31. Safdari Y, Farajnia S, Asgharzadeh M, Khalili M (2013). Antibody humanization methods - a review and update. Biotechnol Genet Eng Rev 29: 175–186.
32. Schiff M (2011). Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 50: 437–449.
33. Scott LJ (2013). Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 73: 857–874.
34. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al. (2014). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509.
35. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
36. Stohl W (2014). Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 18: 473–489.
37. Tanaka T, Narazaki M, Kishimoto T (2012). Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52: 199–219.
38. Tiligada E, Ishii M, Riccardi C, Spedding M, Simon HU, Teixeira MM et al. (2015). The expanding role of immunopharmacology: IUPHAR Review 16. Br J Pharmacol 172: 4217–4227.
39. Tugwell P, Welch V, Suarez-Almazor M, Shea B, Wells G (2000). Efficacy and toxicity of old and new disease modifying antirheumatic drugs. Ann Rheum Dis 59: i32–i35.
40. Vuitton L, Koch S, Peyrin-Biroulet L (2013). Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr Drug Targets 14: 1385–1391.
41. Yamaoka K (2016). Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32: 29–33.